<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Tuberc Other Mycobact Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Tuberc Other Mycobact Dis</journal-id><journal-id journal-id-type="pmc-domain-id">3748</journal-id><journal-id journal-id-type="pmc-domain">jctube</journal-id><journal-title-group><journal-title>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</journal-title></journal-title-group><issn pub-type="epub">2405-5794</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12476092</article-id><article-id pub-id-type="pmcid-ver">PMC12476092.1</article-id><article-id pub-id-type="pmcaid">12476092</article-id><article-id pub-id-type="pmcaiid">12476092</article-id><article-id pub-id-type="doi">10.1016/j.jctube.2025.100561</article-id><article-id pub-id-type="pii">S2405-5794(25)00052-X</article-id><article-id pub-id-type="publisher-id">100561</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><italic toggle="yes">Mycobacterium tuberculosis</italic> infection status and associated factors among household close contacts of rifampicin-resistant pulmonary tuberculosis patients: A single-center cross-sectional study</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name name-style="western"><surname>Shi</surname><given-names initials="Z">Zhengyu</given-names></name><email>showershizhengyu@126.com</email><xref rid="af005" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au010"><name name-style="western"><surname>Peng</surname><given-names initials="J">Juan</given-names></name><xref rid="af010" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au015"><name name-style="western"><surname>Li</surname><given-names initials="X">Xiu</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au020"><name name-style="western"><surname>Fu</surname><given-names initials="X">Xiaoyan</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au025"><name name-style="western"><surname>Zou</surname><given-names initials="L">Liping</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au030"><name name-style="western"><surname>Chen</surname><given-names initials="Q">Qin</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au035"><name name-style="western"><surname>Huang</surname><given-names initials="T">Tao</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au040"><name name-style="western"><surname>Zhou</surname><given-names initials="Y">Yu</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au045"><name name-style="western"><surname>Zhu</surname><given-names initials="H">Hongmei</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au050"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yi</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au055"><name name-style="western"><surname>Tang</surname><given-names initials="S">Shenjie</given-names></name><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au060"><name name-style="western"><surname>Wu</surname><given-names initials="G">Guihui</given-names></name><email>wghwgh2584@sina.com</email><xref rid="af005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="af005"><label>a</label>Public Health Clinical Center of Chengdu, Sichuan Province, Chengdu, China</aff><aff id="af010"><label>b</label>The First Affiliated Hospital of Chengdu Medical College, Sichuan Province, Chengdu, China</aff><aff id="af015"><label>c</label>Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding authors. <email>showershizhengyu@126.com</email><email>wghwgh2584@sina.com</email></corresp><fn id="fn1"><label>1</label><p id="np030">Co-first author: Zhengyu Shi, Juan Peng.</p></fn></author-notes><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>12</day><month>9</month><year>2025</year></pub-date><volume>41</volume><issue-id pub-id-type="pmc-issue-id">494794</issue-id><elocation-id>100561</elocation-id><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 10:25:15.653"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by Elsevier Ltd.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="ab005"><sec><title>Background</title><p>Rifampicin-resistant tuberculosis (RR-TB) is a major global public health challenge. Household close contacts (HHCs) of RR-TB patients face a high risk of <italic toggle="yes">Mycobacterium tuberculosis</italic> infection. Southwestern China carries a heavy RR-TB burden, yet research data on the infection status of this population remain scarce. This study aimed to evaluate the incidence of latent tuberculosis infection (LTBI) and active tuberculosis disease (TBD) and their associated factors among HHCs of RR-TB patients in this region through active screening, providing data support for optimizing regional RR-TB prevention and control strategies.</p></sec><sec><title>Methods</title><p>Using a cross-sectional design, HHCs of RR-TB patients diagnosed at Chengdu Public Health Clinical Medical Center from October 1, 2023, to March 30, 2025, were enrolled. Clinical data were collected via a self-designed questionnaire including gender, age, body mass index (BMI), relationship to index case, living environment, chronic comorbidities, medication history, and TBD-suspicious symptom screening. TBD screening used chest digital radiography (DR) or computed tomography (CT). Clinical data of index cases were extracted from the hospital information system (HIS), covering sputum acid-fast bacillus smear, sputum mycobacterial culture, sputum molecular testing for M. tuberculosis, fluoroquinolone resistance, extent of pulmonary lesions, and cavitation status. TB infection screening employed tuberculin skin test (TST), ESAT6-CFP10 fusion protein skin test (EC), or interferon-&#947; release assays (IGRA). Infection status was categorized as uninfected, LTBI, or TBD based on screening results, clinical symptoms, and imaging findings. Incidence rates of LTBI and TBD were calculated. Chi-square tests compared clinical characteristics across infection states. Multivariable logistic regression analyzed factors associated with LTBI and TBD (versus uninfected).</p></sec><sec><title>Results</title><p>264 HHCs from 197 RR-TB index cases were included: 113 males (42.8&#160;%), 151 females (57.2&#160;%), aged 3&#8211;78&#160;years (mean 42.4&#160;&#177;&#160;15.1). Among 209 participants tested with TST: 117 (44.3&#160;%) had induration diameter [0, 5) mm, 17 (6.4&#160;%) [5, 10) mm, 30 (11.4&#160;%) [10, 15) mm, 45 (17.1&#160;%)&#160;&#8805;&#160;15&#160;mm. Among 46 EC-tested: 29 (11.0&#160;%) had [0, 5) mm, 17 (6.4&#160;%)&#160;&#8805;&#160;5 mm. Among 9 IGRA-tested: 1 (0.4&#160;%) negative, 8 (3.0&#160;%) positive. After cluster-effect adjustment, LTBI incidence was 31.2&#160;% (95&#160;% confidence interval [CI]: 25.8&#8211;38.3), TBD incidence 9.9&#160;% (95&#160;% CI: 6.4&#8211;13.6). The proportion of spousal relationships to index cases was higher in LTBI/TBD groups than uninfected (P&#160;&lt;&#160;0.05). BMI&#160;&lt;&#160;18.5&#160;kg/m<sup>2</sup> and positive TBD symptom screening were more frequent in TBD than uninfected/LTBI groups (P&#160;&lt;&#160;0.05). Pulmonary cavitation in index cases was more common in TBD contacts (P&#160;&lt;&#160;0.05). Multivariable analysis showed spousal relationship was an independent associated factor for LTBI (adjusted odds ratio [aOR]&#160;=&#160;2.102, 95&#160;% CI&#160;=&#160;1.201&#8211;3.677; P&#160;=&#160;0.009). Factors associated with TBD included: spousal relationship (aOR&#160;=&#160;3.949, 95&#160;% CI&#160;=&#160;1.553&#8211;10.042; P&#160;=&#160;0.004), positive TBD symptoms (aOR&#160;=&#160;41.988, 95&#160;% CI&#160;=&#160;4.270&#8211;412.886; P&#160;=&#160;0.001), and pulmonary cavitation in index case (aOR&#160;=&#160;2.881, 95&#160;% CI&#160;=&#160;1.103&#8211;7.523; P&#160;=&#160;0.031).</p></sec><sec><title>Conclusion</title><p>High LTBI and TBD rates exist among RR-TB HHCs in this region. Spousal relationship is a risk factor for both LTBI and TBD; positive TBD symptoms and pulmonary cavitation in index cases correlate with TBD. Active screening for RR-TB HHCs and risk-stratified control strategies are recommended to block transmission chains.</p></sec></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Tuberculosis</kwd><kwd>Rifampicin-resistant tuberculosis</kwd><kwd>Latent tuberculosis infection (LTBI)</kwd><kwd>Close contacts</kwd><kwd>Cross-sectional study</kwd><kwd>Associated factors</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0005">In 2023, an estimated 410,000 new cases of rifampicin-resistant tuberculosis (RR-TB) occurred globally, with a treatment success rate of only 68&#160;% [<xref rid="b0005" ref-type="bibr">1</xref>]. Epidemiological models indicate that RR-TB caused approximately 6.9 million disability-adjusted life years (DALYs) lost worldwide, with Asia bearing a particularly prominent disease burden [<xref rid="b0010" ref-type="bibr">2</xref>]. <italic toggle="yes">Mycobacterium tuberculosis</italic> (MTB) is primarily transmitted via respiratory routes. Studies demonstrate that RR-TB carries a higher transmission risk compared to drug-susceptible tuberculosis [<xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0025" ref-type="bibr">[5]</xref>]. Its household close contacts (HHCs) face substantial infection risks and represent a high-risk population for RR-TB exposure, with a cumulative MTB infection rate reaching 21.6&#160;% within one year, and a cumulative incidence of active tuberculosis disease (TBD) of 2.3&#160;% [<xref rid="b0015" ref-type="bibr">3</xref>]. Modeling estimates further suggest a global prevalence of latent tuberculosis infection (LTBI) associated with RR-TB of approximately 0.3&#160;% [<xref rid="b0030" ref-type="bibr">6</xref>]. LTBI carries a lifelong risk of progression to TBD and becoming a new transmission source, exacerbating RR-TB spread. The combination of low treatment success and high transmission rates poses a major challenge to the End TB Strategy.</p><p id="p0010">As a high-burden country for both TB and drug-resistant TB, China faces severe control challenges. However, real-world data on RR-TB infection status remain scarce. The Public Health and Clinical Center of Chengdu (CDPHCC), the foremost TB diagnosis and treatment facility in southwestern China, plays a pivotal role in regional drug-resistant TB control. This center initiated a cross-sectional survey using active case-finding to evaluate LTBI and TBD incidence among RR-TB patients&#8217; HHCs in this region and identify associated risk factors, thereby providing evidence to optimize precision RR-TB control strategies.</p></sec><sec id="s0010"><label>2</label><title>Methods</title><sec id="s0015"><label>2.1</label><title>Study population and setting</title><p id="p0015">This single-center cross-sectional study was conducted at CDPHCC with approval from its Ethics Committee. From October 1, 2023, to March 31, 2025, HHCs of RR-TB patients meeting inclusion criteria were consecutively enrolled from the Tuberculosis Department of CDPHCC.</p></sec><sec id="s0020"><label>2.2</label><title>Inclusion and exclusion criteria</title><p id="p0020">(1) Inclusion criteria: &#9312; Family members confirmed as RR-TB patients by molecular or phenotypic drug susceptibility testing of sputum; &#9313; Direct co-residence with the index case (confirmed RR-TB family member) for&#160;&#8805;&#160;3 months before diagnosis until 14&#160;days after treatment initiation [<xref rid="b0035" ref-type="bibr">7</xref>,<xref rid="b0040" ref-type="bibr">8</xref>]; &#9314; Signed informed consent (provided by legal guardians for participants&#160;&lt;&#160;18&#160;years). (2) Exclusion criteria: &#9312; Confirmed active tuberculosis disease (TBD) or prior TB history; &#9313; Non-tuberculous mycobacterial infection not ruled out; &#9314; Pregnancy. (3) Withdrawal criteria: &#9312; Post-enrollment discovery of exclusion criteria; &#9313; Participant-initiated withdrawal.</p></sec><sec id="s0025"><label>2.3</label><title>Study methods</title><p id="p0025">(1) Clinical data were collected using a self-designed questionnaire developed through literature review, expert consultation, and research team discussions. Uniformly trained investigators conducted face-to-face interviews. Questionnaire items included: gender, age, body mass index (BMI), relationship to index case, residence (urban/farming-pastoral areas), comorbidities and medication history (diabetes, cardiovascular/endocrine diseases, malignancy, AIDS, long-term glucocorticoid/immunosuppressant use), and TBD symptom screening (cough, fever, night sweats, weight loss). (2) Index case data extracted: sputum acid-fast bacillus (AFB) smear, mycobacterial culture, molecular test results, and chest imaging features. (3) Participants underwent one TB infection test (per preference): tuberculin skin test (TST), ESAT6-CFP10 fusion protein skin test (EC), or interferon-&#947; release assays (IGRAs). (4) Chest digital radiography (DR) or computed tomography (CT) screened for TB; those with imaging abnormalities received confirmatory pathogen testing. (5) Participants were categorized as uninfected, latent TB infection (LTBI), or TBD. Intergroup differences were analyzed via univariate analysis. (6) Factors with statistical significance in univariate analysis were included in multivariable analysis to identify independent risk factors for <italic toggle="yes">Mycobacterium tuberculosis</italic> infection (LTBI/TBD).</p></sec><sec id="s0030"><label>2.4</label><title>Outcomes and definitions</title><p id="p0030">Primary outcomes: LTBI and TBD incidence. MTB infection was defined by any of: &#9312; PPD induration&#160;&#8805;&#160;5 mm in children&#160;&lt;&#160;5 years without BCG vaccination, HIV+, &#8805;1-month immunosuppressant use, or exposure to bacteriologically confirmed pulmonary TB; &#9313; PPD induration&#160;&#8805;&#160;10&#160;mm in BCG-vaccinated individuals; &#9314; EC erythema and/or induration&#160;&#8805;&#160;5 mm; &#9315; IGRA positivity. LTBI: Positive MTB infection without TBD symptoms or chest imaging findings [<xref rid="b0035" ref-type="bibr">7</xref>,<xref rid="b0040" ref-type="bibr">8</xref>]. TBD: Positive MTB infection with chest imaging consistent with active TB, with or without symptoms or bacteriological confirmation [<xref rid="b0045" ref-type="bibr">9</xref>].</p></sec><sec id="s0035"><label>2.5</label><title>Statistical analysis</title><p id="p0035">Statistical analysis was performed using R software (version 4.4.1). Categorical data are presented as &#8220;n (%)&#8221;; normally distributed continuous variables as &#8220;mean&#160;&#177;&#160;standard deviation&#8221;; non-normally distributed variables as &#8220;median (Q1, Q3)&#8221;. Chi-square tests and one-way ANOVA compared characteristics across infection states. Multinomial logistic regression identified independent risk factors for MTB infection. Clustering effects were adjusted via generalized estimating equations (GEE). Testing was 2-sided with significance set at P&#160;&lt;&#160;0.05 based on score tests.</p></sec></sec><sec id="s0040"><label>3</label><title>Results</title><sec id="s0045"><label>3.1</label><title>Demographic data</title><p id="p0040">A total of 264 HHCs from 197 RR-TB index cases were enrolled, including 113 males (42.8&#160;%) and 151 females (57.2&#160;%), aged 3&#8211;78&#160;years (mean 42.4&#160;&#177;&#160;15.1&#160;years).</p></sec><sec id="s0050"><label>3.2</label><title>Mycobacterium tuberculosis infection status</title><p id="p0045">Among participants, 209 (79.2&#160;%) underwent TST, 46 (17.4&#160;%) received EC, and 9 (3.4&#160;%) completed IGRA (<xref rid="t0005" ref-type="table">Table 1</xref>). Ten (3.8&#160;%) had suspected TBD symptoms, and 26 (9.8&#160;%) showed active TBD features on chest imaging. Based on comprehensive MTB infection screening results, clinical symptoms, and chest imaging findings, all participants were classified as uninfected (n&#160;=&#160;153,58.0&#160;%), LTBI (n&#160;=&#160;85,32.2&#160;%), or TBD (n&#160;=&#160;26,9.8&#160;%). After GEE adjustment for clustering effects, LTBI incidence was 31.2&#160;% (95&#160;% confidence interval [CI]: 25.8&#8211;38.3) and TBD incidence 9.9&#160;% (95&#160;% CI: 6.4&#8211;13.6).<table-wrap position="float" id="t0005" orientation="portrait"><label>Table 1</label><caption><p><italic toggle="yes">Mycobacterium tuberculosis</italic> screening results of household contacts of Rifampicin-Resistant Tuberculosis patients (n&#160;=&#160;264).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Detection method</th><th colspan="1" rowspan="1">Result</th><th colspan="1" rowspan="1">N (%)</th></tr></thead><tbody><tr><td rowspan="5" colspan="1">Tuberculin skin test (TST), mm</td><td colspan="1" rowspan="1">Absent</td><td colspan="1" rowspan="1">55(20.8)</td></tr><tr><td colspan="1" rowspan="1">[0, 5)</td><td colspan="1" rowspan="1">117(44.3)</td></tr><tr><td colspan="1" rowspan="1">[5, 10)</td><td colspan="1" rowspan="1">17(6.4)</td></tr><tr><td colspan="1" rowspan="1">[10, 15)</td><td colspan="1" rowspan="1">30(11.4)</td></tr><tr><td colspan="1" rowspan="1">&#8805;15</td><td colspan="1" rowspan="1">45(17.1)</td></tr><tr><td rowspan="3" colspan="1">ESAT6-CFP10 (EC), mm</td><td colspan="1" rowspan="1">Absent</td><td colspan="1" rowspan="1">218(82.6)</td></tr><tr><td colspan="1" rowspan="1">[0, 5)</td><td colspan="1" rowspan="1">29(11.0)</td></tr><tr><td colspan="1" rowspan="1">&#8805;5</td><td colspan="1" rowspan="1">17(6.4)</td></tr><tr><td rowspan="3" colspan="1">Interferon-&#947; release assays (IGRA)</td><td colspan="1" rowspan="1">Absent</td><td colspan="1" rowspan="1">255(96.6)</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">1(0.4)</td></tr><tr><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">8(3.0)</td></tr></tbody></table></table-wrap></p><p id="p0050">Among 26 TBD cases, 8 had bacteriologically confirmed TB: all 8 were acid-fast bacillus (AFB) smear-negative, but positive by molecular testing and culture; drug susceptibility testing identified RR-TB in 7 and rifampicin-susceptible TB in 1. The remaining 18 were clinically diagnosed based on symptoms and imaging without bacteriological confirmation.</p></sec><sec id="s0055"><label>3.3</label><title>Comparison of clinical characteristics across infection states</title><p id="p0055">Contacts with a spousal relationship to the index case showed a higher proportion in LTBI and TBD groups versus uninfected (P&#160;&lt;&#160;0.05); BMI&#160;&lt;&#160;18.5&#160;kg/m<sup>2</sup> and positive TBD symptom screening were more frequent in TBD than uninfected and LTBI groups (P&#160;&lt;&#160;0.05); among index case-related factors, pulmonary cavitation was more prevalent in TBD contacts compared to uninfected and LTBI groups (P&#160;&lt;&#160;0.05), as detailed in <xref rid="t0010" ref-type="table">Table 2</xref>.<table-wrap position="float" id="t0010" orientation="portrait"><label>Table 2</label><caption><p>Variations in clinical characteristics among household contacts of rifampicin-resistant tuberculosis patients by infection status (n&#160;=&#160;264).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Characteristics</th><th colspan="3" rowspan="1"><italic toggle="yes">Mycobacterium tuberculosis</italic> infection status, n(%)</th><th rowspan="2" colspan="1">p-value</th></tr><tr><th colspan="1" rowspan="1">Uninfected individuals, n&#160;=&#160;153</th><th colspan="1" rowspan="1">Latent tuberculosis infection (LTBI), n&#160;=&#160;85</th><th colspan="1" rowspan="1">Tuberculosis disease (TBD), n&#160;=&#160;26</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Household contacts (HHCs)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Gender</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.656</td></tr><tr><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">87(56.9)</td><td colspan="1" rowspan="1">47(55.3)</td><td colspan="1" rowspan="1">17(65.4)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">66(43.1)</td><td colspan="1" rowspan="1">38(44.7)</td><td colspan="1" rowspan="1">9(34.6)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Age, years</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.762</td></tr><tr><td colspan="1" rowspan="1">&#8804;40</td><td colspan="1" rowspan="1">68(44.4)</td><td colspan="1" rowspan="1">34(40.0)</td><td colspan="1" rowspan="1">12(46.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&gt;40</td><td colspan="1" rowspan="1">85(55.6)</td><td colspan="1" rowspan="1">51(60.0)</td><td colspan="1" rowspan="1">14(53.8)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Body mass index (BMI), kg/m<sup>2</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.014</td></tr><tr><td colspan="1" rowspan="1">&lt;18.5</td><td colspan="1" rowspan="1">13(8.5)</td><td colspan="1" rowspan="1">4(4.7)</td><td colspan="1" rowspan="1">6(23.1)<xref rid="tblfn4" ref-type="table-fn">d</xref>, <xref rid="tblfn5" ref-type="table-fn">e</xref></td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#8805;18.5</td><td colspan="1" rowspan="1">140(91.5)</td><td colspan="1" rowspan="1">81(95.3)</td><td colspan="1" rowspan="1">20(76.9)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Relationship to index case</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Spouse</td><td colspan="1" rowspan="1">45(29.4)</td><td colspan="1" rowspan="1">41(48.2)<xref rid="tblfn4" ref-type="table-fn">d</xref></td><td colspan="1" rowspan="1">16(61.5)<xref rid="tblfn4" ref-type="table-fn">d</xref></td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Others</td><td colspan="1" rowspan="1">108(70.6)</td><td colspan="1" rowspan="1">44(51.8)</td><td colspan="1" rowspan="1">10(38.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Residence</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.561</td></tr><tr><td colspan="1" rowspan="1">Agricultural and pastoral areas</td><td colspan="1" rowspan="1">61(39.9)</td><td colspan="1" rowspan="1">40(47.1)</td><td colspan="1" rowspan="1">11(42.3)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Urban areas</td><td colspan="1" rowspan="1">92(60.1)</td><td colspan="1" rowspan="1">45(52.9)</td><td colspan="1" rowspan="1">15(57.7)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">History of chronic diseases and immunosuppressive medication use<xref rid="tblfn1" ref-type="table-fn">a</xref></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.164</td></tr><tr><td colspan="1" rowspan="1">Absent</td><td colspan="1" rowspan="1">145(94.8)</td><td colspan="1" rowspan="1">79(92.9)</td><td colspan="1" rowspan="1">22(84.6)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Present</td><td colspan="1" rowspan="1">8(5.2)</td><td colspan="1" rowspan="1">6(7.1)</td><td colspan="1" rowspan="1">4(15.4)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Smoking history</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.999</td></tr><tr><td colspan="1" rowspan="1">Absent</td><td colspan="1" rowspan="1">124(81.0)</td><td colspan="1" rowspan="1">69(81.2)</td><td colspan="1" rowspan="1">21(80.8)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Present</td><td colspan="1" rowspan="1">29(19.0)</td><td colspan="1" rowspan="1">16(18.8)</td><td colspan="1" rowspan="1">5(19.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Alcohol consumption history</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.783</td></tr><tr><td colspan="1" rowspan="1">Absent</td><td colspan="1" rowspan="1">121(79.1)</td><td colspan="1" rowspan="1">69(81.2)</td><td colspan="1" rowspan="1">22(84.6)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Present</td><td colspan="1" rowspan="1">32(20.9)</td><td colspan="1" rowspan="1">16(18.8)</td><td colspan="1" rowspan="1">4(15.4)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">BCG<xref rid="tblfn2" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.358</td></tr><tr><td colspan="1" rowspan="1">Absent</td><td colspan="1" rowspan="1">54(35.3)</td><td colspan="1" rowspan="1">32(37.6)</td><td colspan="1" rowspan="1">13(50.0)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Present</td><td colspan="1" rowspan="1">99(64.7)</td><td colspan="1" rowspan="1">53(62.4)</td><td colspan="1" rowspan="1">13(50.0)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Suspected active tuberculosis symptoms<xref rid="tblfn3" ref-type="table-fn">c</xref></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">Absent</td><td colspan="1" rowspan="1">152(99.3)</td><td colspan="1" rowspan="1">81(95.3)</td><td colspan="1" rowspan="1">21(80.8)<xref rid="tblfn4" ref-type="table-fn">d</xref>, <xref rid="tblfn5" ref-type="table-fn">e</xref></td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Present</td><td colspan="1" rowspan="1">1(0.7)</td><td colspan="1" rowspan="1">4(4.7)</td><td colspan="1" rowspan="1">5(19.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Chest imaging findings suggestive of pulmonary tuberculosis</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.999</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">153(100.0)</td><td colspan="1" rowspan="1">85(100.0)</td><td colspan="1" rowspan="1">0(0.0)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0(0.0)</td><td colspan="1" rowspan="1">0(0.0)</td><td colspan="1" rowspan="1">26(100.0)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Index case</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Fluoroquinolone resistance</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.704</td></tr><tr><td colspan="1" rowspan="1">Susceptible/unknown</td><td colspan="1" rowspan="1">112(73.2)</td><td colspan="1" rowspan="1">64(75.3)</td><td colspan="1" rowspan="1">21(80.8)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Resistant</td><td colspan="1" rowspan="1">41(26.8)</td><td colspan="1" rowspan="1">21(24.7)</td><td colspan="1" rowspan="1">5(19.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Sputum acid-fast bacilli smear</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.743</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">69(45.1)</td><td colspan="1" rowspan="1">40(47.1)</td><td colspan="1" rowspan="1">10(38.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">84(54.9)</td><td colspan="1" rowspan="1">45(52.9)</td><td colspan="1" rowspan="1">16(61.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Molecular biological testing for <italic toggle="yes">M. tuberculosis</italic></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.398</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">5(3.3)</td><td colspan="1" rowspan="1">6(7.1)</td><td colspan="1" rowspan="1">1(3.8)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">148(96.1)</td><td colspan="1" rowspan="1">79(92.9)</td><td colspan="1" rowspan="1">28(96.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">M. tuberculosis</italic> Culture</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.127</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">30(19.6)</td><td colspan="1" rowspan="1">24(28.2)</td><td colspan="1" rowspan="1">3(11.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">123(80.4)</td><td colspan="1" rowspan="1">61(71.8)</td><td colspan="1" rowspan="1">23(88.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Lung fields involved by lesions</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.982</td></tr><tr><td colspan="1" rowspan="1">&#8804;3</td><td colspan="1" rowspan="1">57(37.3)</td><td colspan="1" rowspan="1">31(36.5)</td><td colspan="1" rowspan="1">10(38.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&gt;3</td><td colspan="1" rowspan="1">96(62.7)</td><td colspan="1" rowspan="1">54(63.5)</td><td colspan="1" rowspan="1">16(61.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Pulmonary cavitation</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.049</td></tr><tr><td colspan="1" rowspan="1">Absent</td><td colspan="1" rowspan="1">91(59.5)</td><td colspan="1" rowspan="1">40(47.1)</td><td colspan="1" rowspan="1">10(38.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Present</td><td colspan="1" rowspan="1">62(40.5)</td><td colspan="1" rowspan="1">45(52.9)</td><td colspan="1" rowspan="1">16(61.5)<xref rid="tblfn4" ref-type="table-fn">d</xref></td><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p id="np005">Chronic diseases include diabetes mellitus, cardiovascular/cerebrovascular diseases, thyroid disorders, malignant neoplasms, chronic kidney disease, and autoimmune disorders; medication history encompasses adrenocortical hormones and immunosuppressive medications.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn2"><label>b</label><p id="np010">For subjects with undocumented BCG vaccination history, vaccination scars were examined; scar presence presumed prior BCG exposure.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn3"><label>c</label><p id="np015">Including fever, cough, chest pain, hemoptysis, night sweats, and weight loss.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn4"><label>d</label><p id="np020"><italic toggle="yes">P</italic> &lt; 0.05 (vs. uninfected individuals).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn5"><label>e</label><p id="np025"><italic toggle="yes">P</italic> &lt; 0.05 (vs. LTBI).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s0060"><label>3.4</label><title>Factors associated with LTBI and TBD</title><p id="p0060">In univariate analysis, spousal relationship to the index case, BMI&#160;&lt;&#160;18.5&#160;kg/m<sup>2</sup>, positive TBD symptom screening, and pulmonary cavitation in index cases showed statistically significant differences across infection states (<xref rid="t0010" ref-type="table">Table 2</xref>); these four factors were included in the multinomial logistic regression model, revealing that spousal relationship was independently associated with LTBI (adjusted odds ratio [aOR]&#160;=&#160;2.102, 95&#160;% CI&#160;=&#160;1.201&#8211;3.677; P&#160;=&#160;0.009); while spousal relationship (aOR&#160;=&#160;3.949, 95&#160;% CI&#160;=&#160;1.553&#8211;10.042; P&#160;=&#160;0.004), positive TBD symptom screening (aOR&#160;=&#160;41.988, 95&#160;% CI&#160;=&#160;4.270&#8211;412.886; P&#160;=&#160;0.001), and pulmonary cavitation in index cases (aOR&#160;=&#160;2.881, 95&#160;% CI&#160;=&#160;1.103&#8211;7.523; P&#160;=&#160;0.031) were independently associated with TBD, as shown in <xref rid="t0015" ref-type="table">Table 3</xref>.<table-wrap position="float" id="t0015" orientation="portrait"><label>Table 3</label><caption><p>Associated factors for LTBI and TBD among household contacts of rifampicin-resistant tuberculosis patients (n&#160;=&#160;264).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="2" rowspan="1">Latent tuberculosis infection (LTBI)</th><th colspan="2" rowspan="1">Active tuberculosis disease (TBD)</th></tr><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">aOR(95&#160;%CI)</th><th colspan="1" rowspan="1">p-value</th><th colspan="1" rowspan="1">aOR(95&#160;%CI)</th><th colspan="1" rowspan="1">p-value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Body mass index (BMI), &lt;18.5&#160;kg/m<sup>2</sup></td><td colspan="1" rowspan="1">0.481(0.145&#8211;1.595)</td><td align="char" colspan="1" rowspan="1">0.231</td><td colspan="1" rowspan="1">2.861(0.842&#8211;9.726)</td><td align="char" colspan="1" rowspan="1">0.092</td></tr><tr><td colspan="1" rowspan="1">Spouse of index case</td><td colspan="1" rowspan="1">2.102(1.201&#8211;3.677)</td><td align="char" colspan="1" rowspan="1">0.009</td><td colspan="1" rowspan="1">3.949(1.553&#8211;10.042)</td><td align="char" colspan="1" rowspan="1">0.004</td></tr><tr><td colspan="1" rowspan="1">Suspected active tuberculosis symptoms</td><td colspan="1" rowspan="1">9.646(0.987&#8211;94.306)</td><td align="char" colspan="1" rowspan="1">0.051</td><td colspan="1" rowspan="1">41.988(4.270&#8211;412.886)</td><td align="char" colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">The index case has a pulmonary cavity</td><td colspan="1" rowspan="1">1.584(0.914&#8211;2.745)</td><td align="char" colspan="1" rowspan="1">0.101</td><td colspan="1" rowspan="1">2.881(1.103&#8211;7.523)</td><td align="char" colspan="1" rowspan="1">0.031</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="s0065"><label>4</label><title>Discussion</title><p id="p0065">The transmission of RR-TB constitutes a severe public health threat. Epidemiological models predict that by 2050, China will experience 60&#160;%, 48&#160;%, and 35&#160;% increases in the incidence, prevalence, and mortality of drug-resistant tuberculosis, respectively&#8212;a growth trend significantly higher than that of drug-susceptible tuberculosis [<xref rid="b0050" ref-type="bibr">10</xref>]. An epidemiological modeling study from China indicates that actively identifying LTBI and implementing interventions is the most cost-effective strategy for controlling RR-TB transmission [<xref rid="b0055" ref-type="bibr">11</xref>]. Therefore, understanding the baseline characteristics of high-risk populations for RR-TB infection in this region is particularly important.</p><p id="p0070">Previous studies report MTB infection rates among RR-TB patients' HHCs ranging from 18.6&#160;% to 40.8&#160;% [<xref rid="b0015" ref-type="bibr">3</xref>,<xref rid="b0020" ref-type="bibr">4</xref>,<xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>], exceeding rates observed in contacts of drug-susceptible TB patients [<xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0025" ref-type="bibr">[5]</xref>]. Variations in infection rates may stem from differences in regional RR-TB burdens and control capacities, with low- and middle-income countries/regions typically bearing higher TB infection burdens than high-income areas [<xref rid="b0025" ref-type="bibr">5</xref>,<xref rid="b0075" ref-type="bibr">15</xref>,<xref rid="b0080" ref-type="bibr">16</xref>]. Participants in this study were primarily recruited from southwestern China&#8212;a region with high domestic TB burden and relatively underdeveloped economic status. Our results show LTBI and TBD incidence rates of 32.2&#160;% and 9.8&#160;%, respectively, higher than reports from southeastern China (an economically more developed region compared to our study area) [<xref rid="b0065" ref-type="bibr">13</xref>]. While IGRA reduce false-positive results, the TST remains a cost-effective screening method in low-income countries [<xref rid="b0080" ref-type="bibr">16</xref>].</p><p id="p0075">This study found that spousal relationship to the index case was significantly associated with both LTBI and TBD in HHCs, suggesting that spouses sharing living spaces and having frequent close contact face elevated infection risks. Positive symptom screening (World Health Organization [WHO]-recommended four-symptom screen: cough, fever, night sweats, weight loss) was significantly associated with TBD, indicating that symptom screening remains a simple, economical, and effective method for early TBD detection. In this study, pulmonary cavitation in index cases correlated with TBD development in HHCs (LTBI incidence was also higher but did not reach statistical significance). The clinical implications are not fully understood but may relate to longer potential disease courses and bacillary excretion durations in cavitary pulmonary TB patients. Other studies have identified malnutrition, advanced age, and low socioeconomic status as factors increasing MTB infection risk among RR-TB patients' HHCs [<xref rid="b0020" ref-type="bibr">4</xref>,<xref rid="b0060" ref-type="bibr">12</xref>,<xref rid="b0065" ref-type="bibr">13</xref>]. Notably, sputum acid-fast bacillus (AFB) smear positivity or mycobacterial culture positivity in index cases did not show association with LTBI or TBD in HHCs in our study. We consider the following primary reasons: RR-TB diagnosis in index cases was primarily made through molecular testing (96.6&#160;% of index cases had positive molecular detection for M. tuberculosis in respiratory specimens, while AFB smear and mycobacterial culture positivity rates were 54.9&#160;% and 78.4&#160;%, respectively). This method has higher sensitivity than conventional AFB smear [<xref rid="b0085" ref-type="bibr">17</xref>,<xref rid="b0090" ref-type="bibr">18</xref>], suggesting that even lower bacterial loads in household environments may pose transmission risks comparable to those of AFB smear-positive patients.</p><p id="p0080">Preventive treatment for LTBI is a critical strategy for controlling TB transmission. Approximately 5&#160;%&#8211;10&#160;% of LTBI cases may progress to TBD [<xref rid="b0095" ref-type="bibr">19</xref>], while preventive therapy achieves 60&#160;%&#8211;90&#160;% efficacy [<xref rid="b0100" ref-type="bibr">20</xref>]. However, no consensus exists on preventive regimens for RR-TB close contacts. WHO recommends 6&#160;months of levofloxacin preventive therapy [<xref rid="b0105" ref-type="bibr">21</xref>], but in our study, approximately one-quarter of index cases contacted by participants had confirmed fluoroquinolone-resistant TB&#8212;higher than global levels [<xref rid="b0110" ref-type="bibr">22</xref>]. Additional index cases had unknown fluoroquinolone resistance (diagnosed only by Xpert MTB/RIF), potentially limiting the applicability of the 6-month levofloxacin regimen in this region. Furthermore, the risk of tendinitis from long-term fluoroquinolone use warrants attention [<xref rid="b0115" ref-type="bibr">23</xref>,<xref rid="b0120" ref-type="bibr">24</xref>]. Most TBD cases (18/26) in this study had negative or no sputum bacteriological confirmation, consistent with our active case-finding strategy using composite diagnostic criteria [<xref rid="b0045" ref-type="bibr">9</xref>]. These cases were detected early when bacterial loads were low and bacillary excretion minimal, enabling better treatment outcomes and earlier transmission interruption. Notably, among 8 bacteriologically confirmed TBD cases, one had rifampicin-susceptible TB confirmed by drug susceptibility testing. In high TB burden countries, infection sources may be complex, and household index cases may not be the sole transmission source. Immunoprophylactic regimens based on vaccines and biologics (e.g., Mycobacterium vaccae vaccine) [<xref rid="b0040" ref-type="bibr">8</xref>,<xref rid="b0125" ref-type="bibr">25</xref>,<xref rid="b0130" ref-type="bibr">26</xref>] prevent LTBI progression to TBD through immunomodulation&#8212;unaffected by the drug resistance profile of the infecting strain&#8212;providing additional options for preventing TB in RR-TB close contacts.</p><p id="p0085">This study has limitations. First, as a single-center study with a limited sample size, we maximized enrollment during the study period to enhance reliability. Second, conducted in a hospital setting, many participants were accompanying persons of index cases; long-term caregiving may increase infection risk, while other family members with less frequent contact were not surveyed, potentially overestimating true infection rates. Additionally, complex transmission chains may exist in high TB burden areas, and we cannot entirely exclude extra-household transmission sources among participants. Whether this affects preventive therapy strategies requires further investigation.</p></sec><sec id="s0070"><label>5</label><title>Conclusion</title><p id="p0090">High LTBI and TBD incidence rates exist among RR-TB patients' HHCs in this region. Spousal relationship increases infection risk, and positive symptom screening correlates with TBD. High-risk populations warrant prioritized attention in clinical practice to enhance RR-TB prevention and control efficiency.</p></sec><sec id="s0075"><title>Ethics approval and consent to participate</title><p id="p0095">Ethical approval was granted by the Public Health Clinical Center of Chengdu Review Board (ethics approval number:YJ-K2023-22&#8211;01). Study participants have given their full consent for publication.</p></sec><sec id="s0080"><title>Funding</title><p id="p0100">This work was funded by the Chengdu Health Commission Chengdu Medical Research Project (No.2023035; No.2023415; No.2024114; No.2023374); Key Research and Development Project of Sichuan Provincial Department of Science and Technology (No.2023YFS0220).</p></sec><sec sec-type="COI-statement" id="coi005"><title>Declaration of competing interest</title><p id="p0105">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><mixed-citation publication-type="other" id="h0005">World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization; 2024. https://iris.who.int/handle/10665/379339.</mixed-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name name-style="western"><surname>Menzies</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Allwood</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>A.S.</given-names></name><etal/></person-group><article-title>Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis</article-title><source>Nat Commun</source><volume>14</volume><year>2023</year><fpage>6182</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-41879-4</pub-id><pub-id pub-id-type="pmid">37794037</pub-id><pub-id pub-id-type="pmcid">PMC10550952</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name name-style="western"><surname>Krishnan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><etal/></person-group><article-title>1-Year incidence of tuberculosis infection and disease among household contacts of rifampin- and multidrug-resistant tuberculosis</article-title><source>Clin Infect Dis</source><volume>77</volume><issue>6</issue><year>2023</year><fpage>892</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1093/cid/ciad345</pub-id><pub-id pub-id-type="pmid">37227925</pub-id><pub-id pub-id-type="pmcid">PMC10681643</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name name-style="western"><surname>Dayal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Tuberculosis burden among household pediatric contacts of adult tuberculosis patients</article-title><source>Indian J Pediatr</source><volume>85</volume><issue>10</issue><year>2018</year><fpage>867</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1007/s12098-018-2648-6</pub-id><pub-id pub-id-type="pmid">29557089</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name name-style="western"><surname>Seid</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alemu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dagne</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Tuberculosis in household contacts of tuberculosis patients in sub-Saharan african countries: a systematic review and meta-analysis</article-title><source>J Clin Tuberc Other Mycobact Dis</source><volume>29</volume><year>2022</year><object-id pub-id-type="publisher-id">100337</object-id><pub-id pub-id-type="doi">10.1016/j.jctube.2022.100337</pub-id><pub-id pub-id-type="pmcid">PMC9678977</pub-id><pub-id pub-id-type="pmid">36425906</pub-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name name-style="western"><surname>Knight</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>McQuaid</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Dodd</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling</article-title><source>Lancet Infect Dis</source><volume>19</volume><issue>8</issue><year>2019</year><fpage>903</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30307-X</pub-id><pub-id pub-id-type="pmid">31281059</pub-id><pub-id pub-id-type="pmcid">PMC6656782</pub-id></element-citation></ref><ref id="b0035"><label>7</label><mixed-citation publication-type="other" id="h0035">Chinese Center for Disease Control and Prevention, National Center for Tuberculosis Control and Prevention. Chinese technical guidelines for tuberculosis control and prevention. Beijing: People's Medical Publishing House; 2021:388.</mixed-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="book" id="h0040"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><part-title>Guidelines for tuberculosis preventive therapy in China</part-title><year>2023</year><publisher-name>People's Medical Publishing House</publisher-name><publisher-loc>Beijing</publisher-loc><fpage>36</fpage><lpage>39</lpage></element-citation></ref><ref id="b0045"><label>9</label><mixed-citation publication-type="other" id="h0045">National Health and Family Planning Commission of the People's Republic of China. WS 288&#8212;2017 Diagnostic criteria for pulmonary tuberculosis. J Tuberc Lung Dis. 2024;5(4):376-378.</mixed-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name name-style="western"><surname>Mehra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cossrow</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kambili</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Assessment of tuberculosis burden in China using a dynamic disease simulation model</article-title><source>Int J Tuberc Lung Dis</source><volume>17</volume><issue>9</issue><year>2013</year><fpage>1186</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.5588/ijtld.12.0927</pub-id><pub-id pub-id-type="pmid">23827732</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z.</given-names></name></person-group><article-title>Estimating the incidence of tuberculosis - shanghai, China, 2025-2050</article-title><source>China CDC Wkly</source><volume>2</volume><issue>52</issue><year>2020</year><fpage>995</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.46234/ccdcw2020.264</pub-id><pub-id pub-id-type="pmid">34594823</pub-id><pub-id pub-id-type="pmcid">PMC8422224</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name name-style="western"><surname>Izudi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Engoru</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bajunirwe</surname><given-names>F.</given-names></name></person-group><article-title>Malnutrition is a risk factor for tuberculosis disease among household contacts: a case-control study in Uganda</article-title><source>IJID Reg</source><volume>12</volume><year>2024</year><object-id pub-id-type="publisher-id">100409</object-id><pub-id pub-id-type="doi">10.1016/j.ijregi.2024.100409</pub-id><pub-id pub-id-type="pmcid">PMC11367089</pub-id><pub-id pub-id-type="pmid">39224535</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Analysis of risk factors for latent Mycobacterium tuberculosis infection among close contacts of drug-resistant pulmonary tuberculosis patients</article-title><source>Chin J Antituberc</source><volume>46</volume><issue>5</issue><year>2024</year><fpage>525</fpage><lpage>530</lpage></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Anh</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Nhung</surname><given-names>N.V.</given-names></name><etal/></person-group><article-title>Latent tuberculous infection in household contacts of multidrug-resistant and newly diagnosed tuberculosis</article-title><source>Int J Tuberc Lung Dis</source><volume>21</volume><issue>3</issue><year>2017</year><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.5588/ijtld.16.0488</pub-id><pub-id pub-id-type="pmid">28225339</pub-id></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mathiasen</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Sch&#246;n</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The global prevalence of latent tuberculosis: a systematic review and meta-analysis</article-title><source>Eur Respir J</source><volume>54</volume><issue>3</issue><year>2019</year><object-id pub-id-type="publisher-id">1900655</object-id><pub-id pub-id-type="doi">10.1183/13993003.00655-2019</pub-id><pub-id pub-id-type="pmid">31221810</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name name-style="western"><surname>Yoopetch</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chitpim</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jittikoon</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Economic evaluation of screening strategy for latent tuberculosis infection (LTBI) in contacts of tuberculosis patients: systematic review and quality assessment</article-title><source>Int J Environ Res Public Health</source><volume>19</volume><issue>20</issue><year>2022</year><fpage>13529</fpage><pub-id pub-id-type="doi">10.3390/ijerph192013529</pub-id><pub-id pub-id-type="pmid">36294107</pub-id><pub-id pub-id-type="pmcid">PMC9603136</pub-id></element-citation></ref><ref id="b0085"><label>17</label><mixed-citation publication-type="other" id="h0085">World Health Organization. WHO consolidated guidelines on tuberculosis: module 3: diagnosis. Geneva: World Health Organization; 2025. https://iris.who.int/handle/10665/381003.<pub-id pub-id-type="pmid">40388555</pub-id></mixed-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name name-style="western"><surname>Bartolomeu-Gon&#231;alves</surname><given-names>G.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>B.T.</given-names></name><etal/></person-group><article-title>Tuberculosis diagnosis: current, ongoing, and future approaches</article-title><source>Diseases</source><volume>12</volume><issue>9</issue><year>2024</year><fpage>202</fpage><pub-id pub-id-type="doi">10.3390/diseases12090202</pub-id><pub-id pub-id-type="pmid">39329871</pub-id><pub-id pub-id-type="pmcid">PMC11430992</pub-id></element-citation></ref><ref id="b0095"><label>19</label><mixed-citation publication-type="other" id="h0095">Hartman-Adams H, Clark K, Juckett G. Update on latent tuberculosis infection [published correction appears in Am Fam Physician. 2014;90(7):434]. Am Fam Physician. 2014;89(11):889-896.<pub-id pub-id-type="pmid">25077395</pub-id></mixed-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name name-style="western"><surname>Zenner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Beer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Treatment of latent tuberculosis infection: an updated network meta-analysis</article-title><source>Ann Intern Med</source><volume>167</volume><issue>4</issue><year>2017</year><fpage>248</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.7326/M17-0609</pub-id><pub-id pub-id-type="pmid">28761946</pub-id></element-citation></ref><ref id="b0105"><label>21</label><mixed-citation publication-type="other" id="h0105">World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. 2nd ed. Geneva: World Health Organization; 2024. https://iris.who.int/handle/10665/378536.<pub-id pub-id-type="pmid">39298638</pub-id></mixed-citation></ref><ref id="b0110"><label>22</label><mixed-citation publication-type="other" id="h0110">World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. https://iris.who.int/handle/10665/363752.</mixed-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name name-style="western"><surname>Barber&#225;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>de la Cuerda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tejeda Gonz&#225;lez</surname><given-names>M.I.</given-names></name><etal/></person-group><article-title>Safety of fluoroquinolones</article-title><source>Rev Esp Quimioter</source><volume>37</volume><issue>2</issue><year>2024</year><fpage>127</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.37201/req/143.2023</pub-id><pub-id pub-id-type="pmid">38140798</pub-id><pub-id pub-id-type="pmcid">PMC10945095</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Adverse reaction signal mining of fluoroquinolone antibiotics in children based on FAERS database</article-title><source>Chin J Hosp Pharm</source><volume>43</volume><issue>17</issue><year>2023</year><fpage>1943</fpage><lpage>1948</lpage></element-citation></ref><ref id="b0125"><label>25</label><mixed-citation publication-type="other" id="h0125">World Health Organization. WHO tuberculosis research and development. Geneva: World Health Organization; 1991:63.</mixed-citation></ref><ref id="b0130"><label>26</label><mixed-citation publication-type="other" id="h0130">Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Instructions for Mycobacterium vaccae for injection. [Accessed 2024-01-01]. http://www.zhifeishengwu.com/d/file/product/ybcp/2021-07-16/aaa5883dde4e566ef7328dbe8c7c29da.pdf.</mixed-citation></ref></ref-list><ack id="ak005"><title>Acknowledgements</title><p id="p0110">We extend our gratitude to all participants for their selfless dedication to this study, and the epidemiologist at CDPHCC for their invaluable support in this study.</p></ack></back></article></pmc-articleset>